Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
MTFB

Motif Bio

$10.11

0.209 (2.11%)

07:09
10/04/17
10/04
07:09
10/04/17
07:09
Recommendations
Motif Bio analyst commentary at H.C. Wainwright »

Motif Bio price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTFB

Motif Bio

$10.11

0.209 (2.11%)

05:38
10/04/17
10/04
05:38
10/04/17
05:38
Hot Stocks
Motif Bio says REVIVE-2 Phase 3 Study of iclaprim met primary endpoint »

Motif Bio announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTFB

Motif Bio

$8.20

0.02 (0.24%)

07:55
09/20/17
09/20
07:55
09/20/17
07:55
Conference/Events
Motif Bio analyst and investor meeting »

Analyst and Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

MTFB

Motif Bio

$8.20

0.02 (0.24%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Motif Bio analyst and investor meeting »

Analyst and Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

Over a month ago
MTFB

Motif Bio

$8.18

0.168 (2.10%)

12:19
09/19/17
09/19
12:19
09/19/17
12:19
Conference/Events
Motif Bio analyst and investor meeting »

Analyst and Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTFB

Motif Bio

$7.65

-0.0999 (-1.29%)

09:37
09/15/17
09/15
09:37
09/15/17
09:37
Hot Stocks
Motif Bio: FDA grants Orphan Drug Designation to iclaprim »

Motif Bio announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTFB

Motif Bio

$7.45

-0.1183 (-1.56%)

06:02
08/09/17
08/09
06:02
08/09/17
06:02
Hot Stocks
Motif Bio second phase 3 clinical trial in ABSSSI finished patient treatment »

Motif Bio announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Over a quarter ago
MTFB

Motif Bio

$7.18

0.03 (0.42%)

05:22
04/18/17
04/18
05:22
04/18/17
05:22
Hot Stocks
Motif Bio REVIVE-1 Phase 3 clinical trial of iclaprim met primary endpoint »

Motif Bio announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTFB

Motif Bio

$6.25

-0.3708 (-5.60%)

18:45
01/30/17
01/30
18:45
01/30/17
18:45
Hot Stocks
Motif Bio says REVIVE-1 trial finishes patient treatment phase »

Motif Bio announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTFB

Motif Bio

$6.02

0.14 (2.38%)

16:12
01/17/17
01/17
16:12
01/17/17
16:12
Hot Stocks
Motif Bio appoints Robert Dickey CFO »

Motif Bio announces that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.